NexImmune (NEXI) Stock Forecast, Price Target & Predictions
NEXI Stock Forecast
NexImmune stock forecast is as follows: an average price target of $3.33 (represents a 1335.34% upside from NEXI’s last price of $0.23) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
NEXI Price Target
The average price target for NexImmune (NEXI) is $3.33 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $2.00. This represents a potential 1335.34% upside from NEXI's last price of $0.23.
NEXI Analyst Ratings
According to 4 Wall Street analysts, NexImmune's rating consensus is 'Buy'. The analyst rating breakdown for NEXI stock is 0 'Strong Buy' (0.00%), 2 'Buy' (50.00%), 2 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
NexImmune Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 16, 2022 | Barclays | $2.00 | $1.19 | 68.11% | 762.07% | |
| Aug 16, 2022 | Raymond James | $3.00 | $1.26 | 138.10% | 1193.10% | |
| Jun 01, 2022 | BTIG | $5.00 | $2.28 | 119.30% | 2055.17% |
The latest NexImmune stock forecast, released on Aug 16, 2022 by Barclays company, set a price target of $2.00, which represents a 68.11% increase from the stock price at the time of the forecast ($1.19), and a 762.07% increase from NEXI last price ($0.23).
NexImmune Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.23 | $0.23 | $0.23 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of NexImmune stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to NexImmune's last price of $0.23. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 16, 2022 | Cantor Fitzgerald | Neutral | Downgrade | |
| Nov 15, 2022 | Raymond James | Outperform | Market Perform | Downgrade |
| Aug 16, 2022 | Barclays | Overweight | Overweight | Hold |
| Aug 16, 2022 | Raymond James | Outperform | Outperform | Hold |
| Jun 01, 2022 | BTIG | Buy | Initialise | |
| Feb 22, 2022 | Raymond James | Outperform | Outperform | Hold |
NexImmune's last stock rating was published by Cantor Fitzgerald on Nov 16, 2022. The company Downgrade its NEXI rating from "null" to "Neutral".
NexImmune Financial Forecast
NexImmune Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| Revenue | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| # Analysts | - | - | - |
| Surprise % | - | - | - |
NexImmune's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NEXI's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
NexImmune EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| EBITDA | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
undefined analysts predict NEXI's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than NexImmune's previous annual EBITDA (undefined) of $NaN.
NexImmune Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| Net Income | - | - | - |
| Avg Forecast | $-510.75K | $-524.55K | $-731.61K |
| High Forecast | $-510.75K | $-524.55K | $-731.61K |
| Low Forecast | $-510.75K | $-524.55K | $-731.61K |
| Surprise % | - | - | - |
NexImmune's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NEXI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
NexImmune SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| SG&A | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
NexImmune's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to NEXI last annual SG&A of $NaN (undefined).
NexImmune EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| EPS | - | - | - |
| Avg Forecast | $-0.37 | $-0.38 | $-0.53 |
| High Forecast | $-0.37 | $-0.38 | $-0.53 |
| Low Forecast | $-0.37 | $-0.38 | $-0.53 |
| Surprise % | - | - | - |
According to undefined Wall Street analysts, NexImmune's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NEXI previous annual EPS of $NaN (undefined).
NexImmune Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| INZY | Inozyme Pharma | $2.94 | $16.00 | 444.22% | Buy |
| PDSB | PDS Bio | $1.96 | $9.00 | 359.18% | Buy |
| CNSP | CNS Pharmaceuticals | $0.11 | $0.50 | 354.55% | |
| ZURA | Zura Bio | $2.51 | $10.00 | 298.41% | Buy |
| IMMX | Immix Biopharma | $2.29 | $7.00 | 205.68% | Buy |
| TERN | Terns Pharmaceuticals | $6.80 | $18.67 | 174.56% | Buy |
| MREO | Mereo BioPharma Group | $3.40 | $8.00 | 135.29% | Buy |
| HOOK | HOOKIPA Pharma | $2.13 | $3.00 | 40.85% | Buy |
| XBIO | Xenetic Biosciences | $4.07 | $4.00 | -1.72% | |
| PALI | Palisade Bio | $1.90 | $1.50 | -21.05% | Buy |